跳至主要内容
临床试验/2024-512888-31-00
2024-512888-31-00招募中4 期

A registry-based, open-label, randomized study to investigate quality-of-life with Plenadren compared with Cortison in participants aged 16-80 with newly diagnosed primary adrenal insufficiency (CORTAD)

Helse Bergen HF14 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年8月7日最近更新:
相关药物

试验速览

阶段
4 期
状态
招募中
入组人数
50
试验地点
14
主要终点
HRQoL score.

研究概览

简要总结

Differences in health-related quality of life (HRQoL) scores in patients receiving Plenadren and conventional Cortisone at time of diagnosis and 1, 6, and 12 months.

研究设计

研究类型
Interventional

入排标准

年龄范围
0 years 至 64 years(0-17 Years, 18-64 Years)
接受健康志愿者

入选标准

  • Age 16-80 years
  • Established PAI according to the diagnostic criteria as specified above.
  • Participants must be recently diagnosed, specifically treated with glucocorticoid replacement therapy for less than 31 days prior to inclusion to secure treatment naivety.
  • Women of childbearing potential (WOCBP) must have a negative pregnancy test performed at the time of screening.
  • Participants must be capable of giving signed informed consent

排除标准

  • High dose glucocorticoid therapy for other disease during last three months prior to screening.
  • Ongoing treatment for active malignant disease.
  • Severe hepatic or renal disease.
  • Sever psychiatric disease.
  • Chronic abuse of alcohol or drug abuse.
  • Current pregnancy, and if the participant plan to become pregnant during the 12 months of study participation.
  • Known hypersensitivity to the active substance or any of the excipients.
  • Participation in another blinded clinical study involving an investigational medicinal product within 1 month prior to study inclusion.

结局指标

主要结局

HRQoL score.

HRQoL score.

次要结局

  • Blood pressure, body weight, waist circumference, body mass index, cholesterols, glucose, insulin, HOMA index.
  • Hair cortisol level, Salivary cortisol day curves, 24 h urine cortisol and metabolites.
  • Sleep diary, actigraphy, sleep radar.
  • Cognitive testing and biomarker for brain plasticity (BDNF) in serum.
  • Bone mineral density, body composition and bone markers
  • Adverse events, Serious adverse events, Adrenal crisis symptoms and treatment.

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Eystein Husebye

Scientific

Helse Bergen HF

研究点 (14)

Loading locations...

相似试验